Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108876 | 0.83 | L3MBTL1 (0.62) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL6569637 | 0.81 | L3MBTL1 (0.60) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| SCHEMBL28177117 | 0.81 | KDM4E (0.40) | L3MBTL1ALOX15HTTALDH1A1KDM4E | |
| SCHEMBL69177 | 0.81 | L3MBTL1 (0.64) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| SCHEMBL21358025 | 0.81 | GABRA1 (0.42) | L3MBTL1ALOX15HTTALDH1A1KDM4E | |
| SCHEMBL6759202 | 0.81 | BRD4 (0.60) | L3MBTL1HTTALDH1A1KDM4ETSHR | |
| SCHEMBL3653582 | 0.80 | L3MBTL1 (0.58) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| SCHEMBL29416324 | 0.79 | L3MBTL1 (0.62) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| SCHEMBL31347575 | 0.79 | L3MBTL1 (0.62) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 | |
| SCHEMBL69990 | 0.79 | L3MBTL1 (0.62) | L3MBTL1ALOX15MAP2K1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20040006226-A1 | Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-01-08 | — | — | US | disclosed |
| WO-2003037904-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2003-05-08 | — | — | WO | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0801648-A4 | SUBSTITUTED 2-ARYLCARBONYLOXYMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | SANOFI WINTHROP INC (US) | 1998-01-28 | — | — | EP | disclosed |
| EP-0801648-A1 | SUBSTITUTED 2-ARYLCARBONYLOXYMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1997-10-22 | — | — | EP | disclosed |
| US-5556909-A | PROTEOLYTIC ENZYME INHIBITOR, TREATMENT OF DEGENERATIVE DISEASES, SUCH AS EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS | SANOFI WINTHROP INC. (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1996016951-A1 | SUBSTITUTED 2-ARYLCARBONYLOXYMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| US-3963733-A | 3-(P-methoxybenzylthio)2-non-oxocarbonylic pyridines | SMITHKLINE CORPORATION (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | L3MBTL1 3399/4885ALOX15 1263/4885MAP2K1 3995/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | L3MBTL1 3393/4885ALOX15 1440/4885MAP2K1 867/4885 |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | HBZ, HBB, HBG2 | L3MBTL1 4612/4885ALOX15 2454/4885MAP2K1 1109/4885 |
| US-20040006226-A1 | Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands | GABRA5, GABRB1, GABRA4 | L3MBTL1 4478/4885ALOX15 1670/4885MAP2K1 4635/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | L3MBTL1 4825/4885ALOX15 4816/4885MAP2K1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.